Advanced search
Publication Cover
Acta Orthopaedica Volume 86, 2015 - Issue 5
Journal homepage
951
Views
24
CrossRef citations to date
0
Altmetric
Original Articles

No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty

A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial

Olle MurenDivision of Orthopedics, Department of Clinical Sciences, Danderyd Hospital and the Karolinska Institute, Stockholm, SwedenCorrespondence[email protected]
,
Ehsan AkbarianDivision of Orthopedics, Department of Clinical Sciences, Danderyd Hospital and the Karolinska Institute, Stockholm, SwedenCorrespondence[email protected]
,
Mats SalemyrDivision of Orthopedics, Department of Clinical Sciences, Danderyd Hospital and the Karolinska Institute, Stockholm, SwedenCorrespondence[email protected]
,
Henrik BodénDivision of Orthopedics, Department of Clinical Sciences, Danderyd Hospital and the Karolinska Institute, Stockholm, SwedenCorrespondence[email protected]
,
Thomas EislerDivision of Orthopedics, Department of Clinical Sciences, Danderyd Hospital and the Karolinska Institute, Stockholm, SwedenCorrespondence[email protected]
,
André StarkDivision of Orthopedics, Department of Clinical Sciences, Danderyd Hospital and the Karolinska Institute, Stockholm, SwedenCorrespondence[email protected]
&
Olof SköldenbergDivision of Orthopedics, Department of Clinical Sciences, Danderyd Hospital and the Karolinska Institute, Stockholm, SwedenCorrespondence[email protected]
 show all
Pages 569-574 | Received 16 Sep 2014, Accepted 14 Mar 2015, Published online: 01 Sep 2015

  • Alfahad A, Thet EM, Radwan F, Sudhakar J, Nini K, Tachtatzis P. Spontaneous Incomplete transverse subtrochanteric femoral fracture with cortical thickening possibly secondary to risedronate use: a case report. J Med Case Rep 2012; 6: 272.
  • Arabmotlagh M, Rittmeister M, Hennigs T. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J Orthop Res 2006; 24(7): 1336-41.
  • Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res 2009; 27(2)183-8.
  • Aspenberg P. Bisphosphonates and implants: an overview. Acta Orthop 2009; 80(1): 119-23.
  • Bodén HS, Sköldenberg OG, Salemyr MO, Lundberg HJ, Adolphson PY. Continuous bone loss around a tapered uncemented femoral stem: a long-term evaluation with DEXA. Acta Orthop 2006; 77(6): 877-85.
  • Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab 2011; 96(11): 3367-73.
  • Hennigs T, Arabmotlagh M, Schwarz A, Zichner L. Dose-dependent prevention of early periprosthetic bone loss by alendronate. Z Orthop Ihre Grenzgeb 2002; 140(1): 42-7.
  • Kim YH, Choi Y, Kim JS. Comparison of bone mineral density changes around short, metaphyseal-fitting, and conventional cementless anatomical femoral components. J Arthroplasty 2011; 26(6): 931-40. e1.
  • Kinov P, Tivchev P, Doukova P, Leithner A. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study. Acta Orthop Belg 2006; 72(1): 44-50.
  • Lindahl H. Epidemiology of periprosthetic femur fracture around a total hip arthroplasty. Injury 2007; 38(6): 651-4.
  • McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344(5): 333-40.
  • Schmidt AH, Kyle RF. Periprosthetic fractures of the femur. Orthop Clin North Am 2002; 33(1): 143-52, ix.
  • Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010; 304(13): 1480-4.
  • Shetty N, Hamer AJ, Stockley I, Eastell R, Willkinson JM. Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension. J Bone Joint Surg Br 2006; 88(10): 1309-15.
  • Sköldenberg OG, Bodén HS, Salemyr MO, Ahl TE, Adolphson PY. Periprosthetic proximal bone loss after uncemented hip arthroplasty is related to stem size: DXA measurements in 138 patients followed for 2-7 years. Acta Orthop 2006;7 7(3): 386-92.
  • Sköldenberg OG, Salemyr MO, Boden HS, Ahl TE, Adolphson PY. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am 2011; 93(20): 1857-64.
  • Sköldenberg OG, Sjoo H, Kelly-Pettersson P, Boden H, Eisler T, Stark A, et al. Good stability but high periprosthetic bone mineral loss and late-occurring periprosthetic fractures with use of uncemented tapered femoral stems in patients with a femoral neck fracture. Acta Orthop 2014; 85(4): 396-402.
  • Streit MR, Merle C, Clarius M, Aldinger PR. Late peri-prosthetic femoral fracture as a major mode of failure in uncemented primary hip replacement. J Bone Joint Surg Br 2011; 93(2): 178-83.
  • Tapaninen TS, Venesmaa PK, Jurvelin JS, Miettinen HJ, Kroger HP. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients. Scand J Surg 2010; 99(4): 32-7.
  • Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res 2001; 16(11): 2126-31.
  • Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19(3): 365-72.
  • Wilkinson JM, Stockley I, Peel NF, Hamer AJ, Elson RA, Barrington NA, et al. Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res 2001; 16(3): 556-64.
  • Wilkinson JM, Eagleton AC, Stockley I, Peel NF, Hamer AJ, Eastell R. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J Orthop Res 2005; 23(1): 1-8.
  • Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int 2007; 18(7): 1009-15.
  • Zhu L, Zheng W, Zhao FC, Guo Y, Meng BY, Liu HT, et al. A meta-analysis of bisphosphonates for periprosthetic bone loss after total joint arthroplasty. J Orthop Sci 2013; 18(5): 762-73.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.